Novartis Kisqali® (ribociclib, LEE011) receives FDA approval
MONALEESA clinical program: a review of ribociclib use in different clinical settings - Oncology Central
CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer?
Kisqali extends survival by 1 year in advanced breast cancer < Pharma < 기사본문 - KBR
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer | British Journal of Cancer
Breast Cancer - ASCO 2021 Breast/Gyn - Breast Cancer and Gynecologic Cancers - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients | Novartis
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - The Breast
Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
MONALEESA Clinical Trial Program in Process: Ribociclib in HR+/HER2- Advanced Breast Cancer
MONALEESA-3/-7 Pooled - Capsule Summary Slidesets - Breast and Gynecologic Cancers - 2020 ASCO Annual Meeting - Oncology - Clinical Care Options
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - ScienceDirect
MONALEESA-2: Overall Survival Benefit Demonstrated in HR+ Advanced Breast Cancer with CDK 4/6 Inhibitor - The Medical Xchange
![PDF] Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/209632dabf2da4cb7603c235e661f27e804de4df/3-Figure1-1.png "PDF] Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer | Semantic Scholar")
PDF] Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer | Semantic Scholar
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Novartis Presents Updated Data on Efficacy, Safety of Kisqali plus Letrozole | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology
Monaleesa Clinical Trials - CancerConnect
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial - The Lancet Oncology
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer - Annals of Oncology
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
ESMO 2016: Press brief on the MONALEESA-2 clinical trial on breast cancer - YouTube
BOOG Study Center - Studie
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer - Annals of Oncology
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial - The Lancet Oncology
MONALEESA-3: Updated Survival
